Lenalidomide: all 818 studies that test it
Page 5 of 9. Open to participants first (111), then studies with results posted, then the rest; newest registration first within each.
- Safety And Efficacy Of Lenalidomide In Patients With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma (NHL)CompletedNCT00179660Phase 2Results posted
- Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple MyelomaCompletedNCT00179647Phase 3Results posted
- Lenalidomide Versus Placebo in Myelodysplastic Syndromes With a Deletion 5q[31] AbnormalityCompletedNCT00179621Phase 3Results posted
- CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's MacroglobulinemiaTerminatedNCT00142168Phase 2Results posted
- Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell TransplantActive, not recruitingNCT00114101Phase 3Results posted
- Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple MyelomaCompletedNCT00112827Phase 1/2Results posted
- Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Complex Regional Pain Syndrome Type 1TerminatedNCT00109772Phase 2Results posted
- Lenalidomide (Revlimid) to Treat Advanced Ocular MelanomaCompletedNCT00109005Phase 2Results posted
- Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple MyelomaActive, not recruitingNCT00098475Phase 3Results posted
- Lenalidomide With or Without Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic LeukemiaCompletedNCT00096044Phase 2Results posted
- CC-5013 With or Without Dexamethasone in Treating Patients With Primary Systemic AmyloidosisCompletedNCT00091260Phase 2Results posted
- A Phase II Study of CC-5013 in MyelofibrosisCompletedNCT00087672Phase 2Results posted
- Lenalidomide Safety/Efficacy in Myelodysplastic Syndromes (MDS) Associated With a Deletion (Del)(5q) Cytogenetic AbnormalityCompletedNCT00065156Phase 2Results posted
- S0232 Dexamethasone With or Without Lenalidomide in Treating Patients With Previously Untreated Stage I, Stage II, or Stage III Multiple MyelomaCompletedNCT00064038Phase 3Results posted
- CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple MyelomaCompletedNCT00056160Phase 3Results posted
- Real-world Study of Lenalidomide After First-line Treatment Lenvatinib With PD-1 in Advanced HCCCompletedNCT07184424Not applicable
- A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell LymphomaWithdrawnNCT07030699Phase 2
- Zanubrutinib, Obinutuzumab and Lenalidomide in Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)Active, not recruitingNCT06547944Phase 1
- A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell LymphomaActive, not recruitingNCT06508658Phase 3
- Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell LymphomaActive, not recruitingNCT06504199Phase 2
- Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell TransplantationWithdrawnNCT06348147Phase 2
- Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5Active, not recruitingNCT06284122Phase 3
- A Study of Glofitamab and Lenalidomide in People With Mantle Cell LymphomaActive, not recruitingNCT06192888Phase 1
- Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular LymphomaActive, not recruitingNCT06191744Phase 3
- Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular LymphomaActive, not recruitingNCT06112847Phase 2
- MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple MyelomaActive, not recruitingNCT06042725Phase 1
- A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's LymphomaActive, not recruitingNCT05950165Phase 1/2
- SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary DiseaseCompletedNCT05900882Phase 2
- Parsaclisib in Patients With Relapsed or Refractory Follicular LymphomaWithdrawnNCT05867030Phase 1
- Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell LymphomaSuspendedNCT05861050Phase 1/2
- Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell LymphomaActive, not recruitingNCT05821088Phase 2
- Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple MyelomaCompletedNCT05804032Phase 3
- GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin LymphomaStatus unknownNCT05797948Not applicable
- Elimination of Minimal Residual Disease After TransplantActive, not recruitingNCT05690984Phase 2
- A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular LymphomaActive, not recruitingNCT05683171Phase 1/2
- Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell LymphomaTerminatedNCT05660967Phase 2
- Immunomodulators on HIV-1 ReservoirStatus unknownNCT05598580Phase 4
- Study of Teclistamab in Combination in Elderly Patients With Multiple MyelomaActive, not recruitingNCT05572229Phase 2
- Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH TrialActive, not recruitingNCT05497804Phase 2
- Lenalidomide in the Treatment of Refractory Cutaneous DermatomyositisStatus unknownNCT05488327Not applicable
- Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)Active, not recruitingNCT05429268Phase 3
- RL-MPV Followed by BBC HCT Using Autologous Stem Cells and Maintenance Therapy With Nivolumab for Newly Diagnosed PCNSLStatus unknownNCT05425654Phase 2
- Efficacy and Safety of Rituximab Plus Zanubrutinib and Lenalidomide for Relapsed and Refractory Diffuse Large B Cell Lymphoma, a Multicenter, Open and Prospective Clinical TrialStatus unknownNCT05392257Phase 2
- GPL in Patients with Relapsed/refractory Diffuse Large B Cell LymphomaActive, not recruitingNCT05335018Phase 2
- A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHLTerminatedNCT05265975Phase 1/2
- A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.WithdrawnNCT05205252Phase 1/2
- A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell LymphomaStatus unknownNCT05200312Phase 2
- A Multicenter In-class Transition Study of Ixazomib Combined With Pomalidomide and Dexamethasone or With Lenalidomide and Dexamethasone in Adults With Relapsed/Refractory Multiple MyelomaWithdrawnNCT05183139Phase 4
- A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal ImpairmentStatus unknownNCT05147493Phase 2
- Isa-RVD Study in Patients With Newly Diagnosed Multiple MyelomaActive, not recruitingNCT05123131Phase 2
- Lenalidomide and Gemcitabine in Relapsed or Refractory Peripheral T-cell LymphomasTerminatedNCT05105412Phase 1/2
- Tislelizumab Combined Treatment in Refractory Extranodal NK/T-cell LymphomaCompletedNCT05058755Not applicable
- ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin LymphomaActive, not recruitingNCT05025800Phase 1/2
- Orelabrutinib in Combination With R2 Regimen for R/R CD20+ B-cell LymphomaStatus unknownNCT05014100Phase 2
- Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop StudyActive, not recruitingNCT04978584Phase 2
- Rituximab,Methotrexate and Lenalidomide in Newly Diagnosed Primary Central Nervous System LymphomaCompletedNCT04934579Phase 2
- Lenalidomide and Dexamethasone for Rosai-Dorfman DiseaseStatus unknownNCT04924647Phase 2
- Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell TransplantActive, not recruitingNCT04876248Phase 2
- Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL PatientsActive, not recruitingNCT04824092Phase 3
- Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple MyelomaActive, not recruitingNCT04822337Phase 1/2
- Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCLStatus unknownNCT04796857Phase 1/2
- Study of Selinexor Plus DRd for Newly Diagnosed Multiple MyelomaActive, not recruitingNCT04782687Phase 2
- DARA RVD For High Risk SMMActive, not recruitingNCT04775550Phase 2
- Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell LymphomaActive, not recruitingNCT04739813Phase 1
- Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM PatientsActive, not recruitingNCT04717700Phase 2
- Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMMActive, not recruitingNCT04653246Phase 2
- Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell LymphomaWithdrawnNCT04635683Phase 1
- Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS LymphomaActive, not recruitingNCT04609046Phase 1
- Lenalidomide and Low-dose Cyclophosphamide for MALT LymphomaStatus unknownNCT04604028Phase 2
- CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell LymphomaCompletedNCT04578600Phase 1
- Lenalidomide Plus R-CHOP for CNS Relapse Prophylaxis in Diffuse Large B-cell LymphomaStatus unknownNCT04544059Phase 2
- Luspatercept and Lenalidomide (L2) in Lower-risk, Non-del(5q) MDS PatientsSuspendedNCT04539236Phase 1/2
- Sintilimab and Lenalidomide as a Treatment for CAEBVStatus unknownNCT04518982Phase 2
- A Study of Health-Related Quality of Life in People With Multiple Myeloma Receiving Daratumumab or LenalidomideActive, not recruitingNCT04497961Phase 2
- Study of Azacytidine Combined With Lenalidomide As Maintenance Therapy Based on MRD Monitoring in AMLStatus unknownNCT04490707Phase 3
- Zanubrutinib, Lenalidomide and Rituximab (ZR2) in Elderly Treatment-naive Patients With Diffuse Large B-cell Lymphoma (DLBCL)Active, not recruitingNCT04460248Phase 2
- An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to TreatmentActive, not recruitingNCT04447716Phase 1
- LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin (R-MPV)Active, not recruitingNCT04446962Phase 1/2
- Lenalidomide in Combination With R-GemOx in First-line Treatment of Elderly Diffuse Large B Cell LymphomaStatus unknownNCT04432402Not applicable
- Lenalidomide in Combination With CHOP in Patients With Untreated PTCLStatus unknownNCT04423926Phase 1/2
- Low-dose Lenalidomide for Non-severe COVID-19 Treatment TrialStatus unknownNCT04361643Phase 4
- Frontline Lenalidomide for AL Amyloidosis Involving MyocardiumCompletedNCT04298372Phase 3
- Carfilzomib, Daratumumab, Lenalidomide and Dexamethasone as First Line Treatment in Multiple MyelomaWithdrawnNCT04288765Phase 3
- Randomized Phase II Study in Elderly Patients With Newly Diagnosed Multiple MyelomaStatus unknownNCT04277845Phase 2
- Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From Advanced Pancreatic CancerCompletedNCT04257448Phase 1/2
- Lenalidomide and Sintilimab for Relapsed/Refractory NK/T-cell LymphomaStatus unknownNCT04231370Phase 2
- A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.Active, not recruitingNCT04224493Phase 3
- Ixazomib, Lenalidomide, and Combination for Maintenance in NDMM PatientsCompletedNCT04217967Phase 4
- R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell LymphomaCompletedNCT04214626Phase 2
- A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With PlasmacytomaActive, not recruitingNCT04174196Phase 2
- R2-MTX With Lenalidomide Maintenance in Newly-diagnosed PCNSL：a Multicenter Phase Ib/II StutyStatus unknownNCT04120350Phase 1/2
- Assessment of Survival and Autonomy With Rituximab Plus Chemotherapy or Rituximab Plus Lenalidomide for Elderly Patients With Relapsed Diffuse Large B-cell LymphomaCompletedNCT04113226Phase 2
- PD1 Antibody and Lenalidomide as a Treatment for EBV-HLH or CAEBVStatus unknownNCT04084626Phase 3
- S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy DurationActive, not recruitingNCT04071457Phase 3
- Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM PatientsCompletedNCT04065789Phase 2
- Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMMCompletedNCT04052880Phase 2
- DNA Vaccination Against NeuroblastomaStatus unknownNCT04049864Early Phase 1
- MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI PatientsCompletedNCT04032626Phase 2
- Biomarker Guided Treatment in DLBCLStatus unknownNCT04025593Phase 2
- Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MMActive, not recruitingNCT04009109Phase 2